Previous 10 | Next 10 |
Evelo Biosciences seeks to harass the ability of microbes in the gut to direct the immune system. The approach is novel and unproven and thus investing is a very high risk proposition. If efficacious, these are benign, inexpensive to manufacture products which can provide treatmen...
-- EDP1908 demonstrates potent anti-tumor effects in murine models of cancer -- -- Oral e xtracellular vesicles have potential to be a completely novel mechanism of I/O therapy -- CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Evelo Bioscie...
-- Treated first patients in Phase 2 dose-ranging trial for EDP1815 in psoriasis -- -- Six clinical readouts in psoriasis, atopic dermatitis, COVID-19, and breast cancer expected over next 3-9 months -- --Advancing newly discovered microbial extracellular vesicles as next-generation SIN...
CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on T...
Galapagos announces topline data from knee osteoarthritis trial. Evelo provides updates for EDP1815 in Atopic Dermatitis and Psoriasis trials. CTI BioPharma initiates NDA process for Pacritinib. For further details see: Galapagos Knee Osteoarthritis Data, And Other News:...
CAMBRIDGE, Mass., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that it will host a key opinion leader discussion on the unmet nee...
Evelo Biosciences ([[EVLO]] -1.3%) has completed enrollment of 24 patients in Phase 1b trial cohort evaluating EDP1815 in mild to moderate atopic dermatitis, ahead of schedule.The trial will evaluate the safety and tolerability of EDP1815 in healthy volunteers and patients with psoriasis or a...
CAMBRIDGE, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that it has completed enrollment of 24 patients in the Phase 1b cli...
Evelo Biosciences (EVLO) has dosed the first patients in its Phase 2 trial evaluating EDP1815 for the treatment of mild to moderate psoriasis. Interim data is expected by mid-2021.The 225-subject will evaluate three doses of the enteric capsule formulation of EDP1815 versus placebo over a 16-...
– Interim data expected by mid-2021 – CAMBRIDGE, Mass., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that it has...
News, Short Squeeze, Breakout and More Instantly...
Evelo Biosciences Inc. Company Name:
EVLO Stock Symbol:
OTCMKTS Market:
Evelo Biosciences Inc. Website:
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...